Important Clinical Safety Alerts
Important updates for all clinical staff at Ryde Hospital.
1. CEC Clinical Management Watch October 2023 - Nasogastric tube insertion & management 2. NSW Health CEC Memo—Publication of 'Direct Oral Anticoagulant (DOAC) Guidelines' & NSW Medicines Formulary information 'Use of Andexanet Alfa in NSW Health facilities' An update on the NSW Health Non - Vitamin K Antagonist oral anticoagulant (NOAC) Guidelines and use of andexanet alfa in NSW Health facilities. The CEC has undertaken a review of the NOAC Guidelines in collaboration with the Anticoagulant Medicines Working Party. The content of the NOAC Guidelines have undergone a comprehensive review to reflect best evidence and current practice and renamed ‘ Direct Oral Anticoagulant (DOAC) Guidelines ’ . The guidelines aim to assist clinicians with the inpatient and outpatient management of patients receiving a DOAC. The DOAC Guidelines replace the NOAC Guidelines previously available on the CEC website and are available here. The NSW Medicines Formulary Committee has reviewed the available evidence for the use of andexanet alfa in the reversal of apixaban and rivaroxaban anticoagulation. Andexanet alfa is not listed on the NSW Medicines Formulary. A summary of the decision not to list andexanet alfa and considerations for use in NSW Health facilities is available at here.
Urgent Care Centre - Top Ryde
3
Made with FlippingBook - professional solution for displaying marketing and sales documents online